Results 1 to 10 of about 1,701 (184)

Lenacapavir como profilaxis preexposición PrEP del Virus de la Inmunodeficiencia Humana [PDF]

Ciencia y Educación
A pesar de los avances en la prevención del VIH, las brechas en adherencia limitan la efectividad de la PrEP oral diaria, especialmente en poblaciones clave.
Diego Steven Guerrero Arroyo, Doris Vanesa Palacios Vargas   +1 more
doaj   +2 more sources

Dollars and dilemmas: lenacapavir’s pricing, patents, and the path to affordability

International Journal for Equity in Health
Lenacapavir (Yeztugo), the world's first twice-yearly human immunodeficiency virus (HIV) prevention injection, offers transformative potential but faces a critical challenge: affordability. While its production cost is estimated at just $25 per person annually, projections place its market price at over $25,000 in high-income settings, a 1000-fold ...
Adepoju, Victor Abiola, Abdulrahim, Abdulrakib   +1 more
openaire   +2 more sources

HIV-1 capsid stability and reverse transcription are finely balanced to minimize sensing of reverse transcription products via the cGAS-STING pathway

mBio
A critical determinant for early post-entry events, the HIV-1 capsid (CA) protein forms the conical core when it rearranges around the dimeric RNA genome and associated viral proteins.
Jenna E. Eschbach, Maritza Puray-Chavez, Shawn Mohammed, Qiankun Wang, Ming Xia, Lin-Chen Huang, Liang Shan, Sebla B. Kutluay   +7 more
doaj   +1 more source

Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor Lenacapavir Among People Living with HIV in Guangdong, China

Infection and Drug Resistance
Yaqing Lin,1,* Xuemei Ling,2,3,* Linghua Li,2,* Ruolei Xin,4 Fengyu Hu,1 Junbin Li,3 Jiaojiao Li,1 Feng Li,1,5 Yun Lan1 1Institute of Infectious Diseases, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, People’s ...
Lin Y, Ling X, Li L, Xin R, Hu F, Li J, Li J, Li F, Lan Y   +8 more
doaj  

Investigation of Natural Resistance to Fostemsavir and Lenacapavir in Naïve Primary Infections by Ultra-Deep Sequencing of near Full-Length HIV-1 Genomes

Viruses
Next-generation sequencing (NGS) of near full-length HIV genomes was performed to investigate natural resistance to Fostemsavir (FTR) and Lenacapavir (LEN) at the quasispecies level in nine naïve primary HIV infections harboring different HIV subtypes ...
Elisabetta Lazzari, Gabriella Rozera, Roberta Gagliardini, Valentina Mazzotta, Lavinia Fabeni, Federica Forbici, Giulia Berno, Cristian Cosentino, Enrico Girardi, Andrea Antinori, Fabrizio Maggi, Isabella Abbate   +11 more
doaj   +1 more source

Lenacapavir (Sunlenca®) for the treatment of HIV-1

Trends in Pharmacological Sciences, 2023
Pratish C. Patel, Heather K. Beasley, Antentor Hinton, Celestine N. Wanjalla   +3 more
openaire   +2 more sources

Lenacapavir-induced capsid damage uncovers HIV-1 genomes emanating from nuclear speckles

The EMBO Journal
Following cell entry, HIV-1 capsids enter the nucleus by passage through nuclear pores and reach nuclear speckles with subsequent uncoating of the reverse-transcribed genome and its integration into speckle-associated chromatin domains.
Thorsten G Müller, Severina Klaus, Vojtech Zila, Bojana Lucic, Carlotta Penzo, Svenja L Nopper, Gonen Golani, Maria Anders-Össwein, Vera Sonntag-Buck, Anke-Mareil Heuser, Ulrich S Schwarz, Vibor Laketa, Marina Lusic, Barbara Müller, Hans-Georg Kräusslich   +14 more
doaj   +1 more source

A Review of Lenacapavir Act as Caspid Inhibitor

International Journal of Advanced Research in Science, Communication and Technology
HIV is an infection that targets the immune system of the body, specifically the CD4 cells, which are white blood cells to prevent the spread of the virus by using medications that alter the HIV genome. The rise of drug-resistant viruses has rendered all antiretroviral medications, including emerging drug classes, largely or completely inert.
null Govind Gupta, null Ankit Goel, null Renu Sharma, null Aarti Yadav   +3 more
openaire   +1 more source

A Concise Route to Lenacapavir Sodium: First Demonstration of One-Pot Heck-Suzuki Coupling in Lenacapavir API Synthesis

This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025).
limei jin, Daryl Guthrie, Anand Shinde, Ramesh Vediyappan, Aline De Souza, Rama Sayini, John Saathoff, Nagaraju Sakkani, Naeem Asad, Sam Hochstetler, Barrack Stubbs, Justina Burns, B. Frank Gupton, Ryan Littich   +13 more
openaire   +1 more source

Expanding Treatment Opportunities: Reviewing the Current State of Injectable Antiretrovirals for Treatment of HIV

Infectious Diseases and Therapy
Antiretroviral therapy has evolved significantly over the last 20–30 years, from requiring multiple tablets multiple times per day to single-tablet regimens and most recently, in 2021, long-acting injectable antiretrovirals.
Amanda Binkley, Matty Zimmerman, Christina Maguire   +2 more
doaj   +1 more source